Elbit proposes to complete purchase of Elscint
This article was originally published in Clinica
Elbit Medical Imaging, the holding company for Elscint, wants to buy up all Elscint shares in an offer worth about $99 million. Elbit already holds a 57% stake in Elscint, and has offered stockholders $14 a share, a 21% premium over the closing price registered on the New York Stock Exchange before the proposal was made on February 17.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.